Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION)
Complete Title: A first-in-human, two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor, in patients with advanced-stage, relapsed/refractory cancer
Trial Phase: I/II
Investigator: Evan Hall
Part 1 will be a dose escalation study of IV ICT01 (a monoclonal antibody targeting BTN3A) as monotherapy in patients with advanced solid or hematologic tumors, followed by a cohort examining the combination of ICT01 plus pembrolizumab (Keytruda). Part 2 will be a cohort expansion into 2-3 solid tumor indications and one hematologic malignancy for ICT01 monotherapy, and 1-2 solid tumor indication receiving ICT01 plus pembrolizumab.
Keywords:
- Solid Tumors
- Leukemia, Lymphoid
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I/II
Evan Hall
RG1121319
NCT04243499
A first-in-human, two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor, in patients with advanced-stage, relapsed/refractory cancer
Solid Tumors
Leukemia, Lymphoid